Tumor Immunology 101: A Navigation Guide for the Growing Field of Cancer Immunotherapy
Friday, October 2, 2015 • 8 a.m. – 4 p.m.
|
|
Specifically designed for clinical oncologists, registered nurses, nurse practitioners, and the entire medical team involved in treating cancer patients with immunotherapy, this introductory, CME- and CNE-certified program provided an understanding of basic immunology principles in the clinical application and management of cancer immunotherapy and discuss emerging drugs and concepts in the cancer immunotherapy field.
Presented by leading authorities in tumor immunology and cancer immunotherapy, this program facilitated understanding of 1) the underlying principles of tumor immunology and immunotherapy, 2) the clinical indications for cancer immunotherapy and appropriate selection of patients, 3) patient management, and 4) the therapeutic effectiveness of immunotherapy to ultimately improve patient outcomes.
Attendees also took advantage of the opportunity for professional networking that promotes collaboration and scientific exchange with experts, clinical oncologists and other health care providers from the surrounding community.
The target audience for this program included clinical oncologists, registered nurses, nurse practitioners, the entire medical team involved in patient care, early career individuals, allied health professionals, and patient advocates who wished to learn principles of tumor immunology and immunotherapy, as well as improve their ability to select patients for immunotherapy and provide state-of-the-art clinical management for their patients.
Upon completion of this program, participants were expected to be able to:
Asim Amin, MD, PhD – Levine Cancer Institute Carolinas Medical Center
Matthew M. Burke, MBA, RN, MSN, APRN-B – Smilow Cancer Hospital at Yale-New Haven
Joseph W. Fay, MD – Baylor University Medical Center
Keith L. Knutson, PhD – Vaccine & Gene Therapy Institute of Florida
Hideho Okada, MD, PhD – University of California San Francisco
John D. Powderly II, MD, CPI – Carolina BioOncology Institute, PLLC
Brian I. Rini, MD – Cleveland Clinic Taussig Cancer Center
Alexander Spira, MD, PhD – Virginia Cancer Specialists
Laura S. Wood, RN, MSN, OCN – Cleveland Clinic Taussig Cancer Center
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and the Society for Immunotherapy of Cancer in collaboration with Postgraduate Institute for Medicine
The Advances in Cancer Immunotherapy™ series is supported in part by independent medical educational grants from AstraZeneca; Bristol-Myers Squibb; Genentech; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation and Prometheus Laboratories Inc.
As with all SITC events, event staff was prepared to accommodate any special needs for this program (i.e., physical, dietary, etc.).
View a list of all upcoming Advances in Cancer ImmunotherapyTM 2015 regional programs.